Welgus Howard G. sold $124K of ARQT

Welgus Howard G. sold 4,730 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.18 ($0.12M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Welgus Howard G.
Published Aug 19, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The modest size and pre‑arranged 10b5‑1 plan suggest limited informational content for traders.

02

Market read

Minor insider sale with negligible trading impact.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: post-filing 2026-08-19

Background

Form 4 filings disclose insider transactions; this is a routine director sale.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Director Welgus Howard G. sold 4,730 shares of ARQT for $123,834 via a 10b5-1 plan.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

The transaction amount is small relative to float and typical insider activity, so market reaction is expected to be minimal.

Market effects

No immediate sector-wide implications; biotech sector remains unchanged.

US market only; no regional effect.

Low global relevance.

Counterpoint

The sale could be purely portfolio rebalancing; investors might view it as non‑signal.

Key entities

  • Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies.

  • Welgus Howard G.

    Director of Arcutis Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.